Company Overview of Biomarck Pharmaceuticals, Ltd.
Biomarck Pharmaceuticals, Ltd., a biopharmaceutical company, develops a portfolio of products utilizing targeted anti-Marcks technology for the treatment of cancer and acute respiratory distress syndrome. It provides BIO-11006, a solution for non small cell lung cancer (NSCLC) and acute respiratory distress syndrome. The company was founded in 2002 and is based in Durham, North Carolina.
Westpark Corporate Center
4364 South Alston Avenue
Durham, NC 27713-2280
Founded in 2002
Key Executives for Biomarck Pharmaceuticals, Ltd.
Similar Private Companies By Industry
|1st Order Pharmaceuticals, Inc.||United States|
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
Recent Private Companies Transactions
December 30, 2016
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|NYC2012, Inc.||United States|
|Tax Management Inc||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Biomarck Pharmaceuticals, Ltd., please visit www.biomarck.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.